BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 18089823)

  • 1. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
    Engelman JA; Zejnullahu K; Gale CM; Lifshits E; Gonzales AJ; Shimamura T; Zhao F; Vincent PW; Naumov GN; Bradner JE; Althaus IW; Gandhi L; Shapiro GI; Nelson JM; Heymach JV; Meyerson M; Wong KK; Jänne PA
    Cancer Res; 2007 Dec; 67(24):11924-32. PubMed ID: 18089823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.
    Ercan D; Zejnullahu K; Yonesaka K; Xiao Y; Capelletti M; Rogers A; Lifshits E; Brown A; Lee C; Christensen JG; Kwiatkowski DJ; Engelman JA; Jänne PA
    Oncogene; 2010 Apr; 29(16):2346-56. PubMed ID: 20118985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
    Pan Y; Xu Y; Feng S; Luo S; Zheng R; Yang J; Wang L; Zhong L; Yang HY; Wang BL; Yu Y; Liu J; Cao Z; Wang X; Ji P; Wang Z; Chen X; Zhang S; Wei YQ; Yang SY
    Mol Cancer Ther; 2012 Apr; 11(4):952-62. PubMed ID: 22319204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
    Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
    PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer.
    Wang SP; Hsu YP; Chang CJ; Chan YC; Chen CH; Wang RH; Liu KK; Pan PY; Wu YH; Yang CM; Chen C; Yang JM; Liang MC; Wong KK; Chao JI
    Biochem Pharmacol; 2021 Nov; 193():114792. PubMed ID: 34597670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
    Godin-Heymann N; Ulkus L; Brannigan BW; McDermott U; Lamb J; Maheswaran S; Settleman J; Haber DA
    Mol Cancer Ther; 2008 Apr; 7(4):874-9. PubMed ID: 18413800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model.
    Hayakawa H; Ichihara E; Ohashi K; Ninomiya T; Yasugi M; Takata S; Sakai K; Matsumoto K; Takigawa N; Tanimoto M; Kiura K
    Cancer Sci; 2013 Nov; 104(11):1440-6. PubMed ID: 24033722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
    Bean J; Brennan C; Shih JY; Riely G; Viale A; Wang L; Chitale D; Motoi N; Szoke J; Broderick S; Balak M; Chang WC; Yu CJ; Gazdar A; Pass H; Rusch V; Gerald W; Huang SF; Yang PC; Miller V; Ladanyi M; Yang CH; Pao W
    Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20932-7. PubMed ID: 18093943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
    Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.
    Suzuki T; Fujii A; Ohya J; Amano Y; Kitano Y; Abe D; Nakamura H
    Cancer Sci; 2007 Dec; 98(12):1977-84. PubMed ID: 17888033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
    Bean J; Riely GJ; Balak M; Marks JL; Ladanyi M; Miller VA; Pao W
    Clin Cancer Res; 2008 Nov; 14(22):7519-25. PubMed ID: 19010870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa.
    Zhang B; Jiao J; Liu Y; Guo LX; Zhou B; Li GQ; Yao ZJ; Zhou GB
    PLoS One; 2012; 7(11):e48748. PubMed ID: 23185274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Detouring Experience Not Recommended: Lessons Learned from PF00299804.
    Li M; Mok K; Mok T
    Cancer Res; 2022 Oct; 82(20):3662-3664. PubMed ID: 36245245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.
    Kuang Y; Rogers A; Yeap BY; Wang L; Makrigiorgos M; Vetrand K; Thiede S; Distel RJ; Jänne PA
    Clin Cancer Res; 2009 Apr; 15(8):2630-6. PubMed ID: 19351754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
    Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
    Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
    J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.